통풍 치료제 시장 : 예측(2026-2031년)

The gout therapeutics market, with a 7.49% CAGR, is forecasted to rise from USD 2.926 billion in 2025 to USD 4.513 billion in 2031.

The gout therapeutics market is experiencing steady growth at a 7.49% CAGR through 2031, driven by increasing disease prevalence, lifestyle changes, and enhanced awareness. Gout therapeutics-treatments specifically designed to manage and alleviate symptoms of this arthritis form caused by uric acid crystal buildup in joints-are becoming increasingly critical as patient populations expand globally. Rising gout prevalence, changing lifestyles, higher obesity rates, ongoing research, product launches, government support, and growing public awareness are propelling market expansion.

Primary Market Drivers

Rising Gout Prevalence

Gout prevalence has increased substantially worldwide, creating sustained demand for effective therapeutics. A nationwide cohort study using Clinical Practice Research Datalink data published in the Annals of Rheumatic Diseases in June 2021 demonstrated that gout prevalence climbed from 0.98% in 1997 to 2.33% in 2021, spanning the COVID-19 pandemic. This more than doubling of prevalence over two decades underscores the growing patient population requiring therapeutic intervention and represents a fundamental driver of market growth as healthcare systems address expanding treatment needs.

Obesity Connection

Obesity and gout are interconnected conditions, with obesity recognized as a significant risk factor for gout development. Overweight individuals, particularly those with abdominal obesity, experience increased uric acid synthesis and decreased uric acid excretion, elevating uric acid levels that precipitate gout. The rising global obesity prevalence is contemplated to substantially aid the gout therapeutics market. Obesity has reached epidemic proportions, causing approximately 2.8 million deaths annually. The World Obesity Atlas 2022 estimates that 1 in 5 women and 1 in 7 men will live with obesity by 2031, indicating sustained pressure on gout therapeutics demand as obesity-related gout cases accumulate.

Lifestyle Factors

Lifestyle choices play crucial roles in gout development, management, and prevention. Certain behaviors-including dietary choices, alcohol consumption, smoking, and stress-can contribute to gout onset or exacerbate symptoms. Alcohol, particularly beer and spirits, has been associated with increased gout risk. Individuals aged 21 and above in the United States consumed an average of 26 gallons of beer and hard cider per person in 2020. This substantial alcohol consumption, combined with changing lifestyle patterns such as sedentary behavior adoption, represents a major growth driver for the gout therapeutics market as these modifiable risk factors remain prevalent in modern societies.

Awareness and Diagnosis Improvements

Increased awareness about gout among healthcare professionals and the general population has led to improved diagnosis rates. Early and accurate diagnosis enables timely treatment initiation, promoting gout therapeutics demand. The CDC's Arthritis Program advises five self-management techniques for treating arthritis and related symptoms that may benefit gout patients. May 22 is celebrated as Gout Awareness Day in America to raise public awareness about adverse effects and treatment options. Organizations including the National Gout Education Society, Alliance for Gout Awareness, and American Association of Kidney Patients actively promote gout awareness. These institutional efforts and rising public consciousness are propelling market growth by ensuring patients seek appropriate medical intervention.

Research and Development Activity

Increasing studies and clinical trials for gout treatment, followed by product launches, are anticipated to boost market growth. D-0120 is under phase II clinical development for gouty arthritis, developed by InventisBio. The phase 3 Dissolve program of SEL-212 developed by Selecta Biosciences to treat chronic refractory gout concluded in March 2023, showing statistically significant higher response rates in patients 50 years and above at high doses in Dissolve I and Dissolve II. These ongoing clinical developments demonstrate industry commitment to advancing therapeutic options and addressing unmet medical needs in gout management.

Market Constraints

Despite positive growth trajectories, the gout therapeutics market faces challenges. Gout demands long-term care and lifestyle modifications, yet some patients struggle with treatment plan adherence, including medication compliance, dietary changes, and healthy lifestyle adoption. Non-compliance may compromise therapeutic effectiveness by raising disease progression risk and resulting in insufficient symptom management. Additionally, adverse effects of gout therapeutics-ranging from minor to serious-may limit market growth. Corticosteroids may produce systemic adverse effects when used over extended periods, potentially deterring some patients from sustained treatment.

Regional Dynamics and Recent Developments

North America is expected to hold significant market share during the forecast period, supported by rising gout incidence, strong healthcare infrastructure, and increasing healthcare expenditure. Health expenditure as a U.S. GDP percentage increased from 16.68% in 2019 to 18.82% in 2020. Major market players including Merck & Co. and Mayo Clinic are expected to bolster regional market growth through enhanced products.

Recent developments underscore ongoing innovation. In August 2022, Synglogic Inc. launched SYNB2081, a new drug candidate for gout treatment developed through synthetic biology in collaboration with Ginkgo Bioworks, designed to lower uric acid levels. The gout therapeutics market continues evolving, propelled by epidemiological trends, research advancement, and growing recognition of gout's clinical and economic burden.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Gout Therapeutics Market Segmentation

• By Drug Class
• NSAIDs
• Corticosteroids
• Colchicine
• Urate-Lowering Agents
• Others
• By Disease Condition
• Acute Gout
• Chronic Gout
• By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GOUT THERAPEUTICS MARKET BY DRUG CLASS

• 5.1. Introduction
• 5.2. NSAIDs
• 5.3. Corticosteroids
• 5.4. Colchicine
• 5.5. Urate-Lowering Agents
• 5.6. Others

6. GOUT THERAPEUTICS MARKET BY DISEASE CONDITION

• 6.1. Introduction
• 6.2. Acute Gout
• 6.3. Chronic Gout

7. GOUT THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Retail Pharmacy
• 7.4. Online Pharmacy

8. GOUT THERAPEUTICS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Takeda Pharmaceutical Company Ltd.
• 10.2. Novartis AG
• 10.3. AstraZeneca plc
• 10.4. Horizon Therapeutics plc
• 10.5. Merck & Co. Inc.
• 10.6. Teijin Pharma Ltd.
• 10.7. GlaxoSmithKline, Plc.
• 10.8. Arthrosi
• 10.9. Mayo Clinic
• 10.10. Johns Hopkins Arthritis Center

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations